Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 942-947

  Small Jr , William ^a   Berlin, Jordan ^a   Freedman, Gary M ^a   Lawrence, Theodore ^a   Talamonti, Mark S ^a   Mulcahy, Mary F ^a   Chakravarthy, A Bapsi ^a   Konski, Andre A ^a   Zalupski, Mark M ^a   Philip, Philip A ^a   Kinsella, Timothy J ^a   Merchant, Nipun B ^a   Hoffman, John P ^a   Benson, Al B ^a   Nicol, Steven ^a   Xu, Rong M ^a   Gill, John F ^a   McGinn, Cornelius J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HYPERGLYCEMIA; JAUNDICE; LEUKOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; STOMACH OBSTRUCTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM STAGING; NEUTROPENIA; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VOMITING;

EID: 39749174027     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.9014     Document Type: Article

References (38)

1. Sindelar WF, Kinsella TJ: Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 10:226-230, 1999 (suppl)
2. Shipley WU, Nardi GL, Cohen AM, et al: Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: A comparative study to surgical resection. Cancer 45:709-714, 1980
3. Mohiuddin M, Cantor RJ, Biermann W et al: Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 14:79-84, 1988
4. Picus J, Myerson R, Drebin J, et al: A phase II trial of continuous infusion (CIVI) 5-FU with 3-D conformal radiation in the adjuvant treatment of pancreatic, ampullary and biliary cancers. Proc Am Soc Clin Oncol 6:16, 1998 (abstr 1023)
5. Milano MT, Chumra SJ, Garafalo MC, et al: Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: Toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 59:445-453, 2004
6. Burris HA, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997
7. Lawrence TS, Chang EY, Hahn TM, et al: Radiosensitization of pancreatic cancer cells by 2-,2-difluor-2-deoxycitadine. Int J Radiat Oncol Biol 34:867-872, 1996
8. Blackstock AW, Bernard SA, Richards F, et al: Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 17:2208-2212, 1999
9. Talamonti MS, Catalano PJ, Vaughn DJ, et al: Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity. J Clin Oncol 18:3384-3389, 2000
10. Wolff RA, Evans DB, Gravel DM, et al: Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 7:2246-2253, 2001
11. McGinn CJ, Zalupski MM, Shureiqi I, et al: Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19:4202-4208, 2001
12. Talamonti MS, Small W, Mulcahy MF, et al: A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 13:150-158, 2006
13. Hall EJ, Giaccia AJ: Time, dose, and fractionation in radiotherapy, in Hall EJ: Radiobiology for the Radiologist. Philadelphia, PA, Lippincott, Williams & Wilkins, 2006, pp 378-397
14. National Cancer Institute Common Toxicity Criteria Version 2.0. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
15. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Pancreatic adenocarcinoma. http://www.nccn.org/professionals/ physicians_gls/PDF/pancreatic.pdf
16. Therasse P, Arbuck S, Eisenhauer E, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Simon R: Optimal two-stage designs for phase II trials. Control Clin Trials 10:1-10, 1989
18. Kaplan E, Meier P: Nonparametric estimation of incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Moessinger RC: Neoadjuvant chemoradiation for pancreatic cancer. US Oncological Disease 51-52, 2006 (June)
20. Ko AH, Hwang J, Venook AP, et al: Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93:195-199, 2005
21. Fogelman DR, Schreibman SM, Fine RL: CA 19-9 level predicts response to GTX chemotherapy in pancreatic cancer. J Clin Oncol 23:16S, 2005 (suppl; abstr 4206)
22. Boeck S, Schulz C, Stieber P, et al: Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: Pretreatment levels or kinetics during chemotherapy? Onkologie 30:39-42, 2007
23. Halm U, Schumann T, Schiefke I, et al: Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82:1013-1016, 2000
24. Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil - The Gastrointestinal Tumor Study Group. Cancer 48:1705-1710, 1981
25. Gastrointestinal Tumor Study Group: Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80:751-755, 1988
26. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59:2006-2010, 1987
27. Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985
28. Klinkenbijl JH, Jeekel J, Sahmoud T, et al: Adjuvant radiotherapy and 5-fluorouracil after curative resection of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group (with discussion). Ann Surg 230:776-784, 1999
29. Neoptolemos JP, Stocken DD, Friess H, et al: ESPAC-1: Final results of a European, randomised controlled trial to assess the roles of adjuvant chemotherapy and adjuvant chemoradiation in resectable pancreatic cancer. Pancreatology 3:209-269, 2003
30. Crane CH, Ben-Josef E, Small W: Chemotherapy for pancreatic cancer: Correspondence to the Editor. N Engl J Med 350:2713-2715, 2004
31. Regine WF, Winter KW, Abrams R, et al: RTOG 9704: a phase III study of adjuvant and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol 24:18S, 2006 (suppl; abstr 4007)
32. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 297:267-277, 2007
33. Spitz FR, Abbruzzese JL, Lee JE, et al: Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 15:928-937, 1997
34. Pisters PWT, Abbruzzese JL, Janjan NA, et al: Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 16:3843-3850, 1998
35. Breslin TM, Hess KR, Harbison DB, et al: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: Treatment variables and survival duration. Ann Surg Oncol 8:123-132, 2001
36. Arnoletti P, Hoffman J, Ross EA, et al: Preoperative chemoradiation in the management of adenocarcinoma of the body of pancreas. Am Surg 68:330-335, 2002
37. Chauffert B, Mornex F, Bonnetain F, et al: Phase III trial comparing chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: A FFCD-SFRO study. J Clin Oncol 24:18S, 2006 (suppl; abstr 4008)
38. Murphy JD, Adusumilli S, Griffith KA, et al: Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Rad Onc Biol Phys 68:801-808, 2007